Sanofi and Regeneron’s medical congress campaign focuses on type 2 inflammation education for docs – FiercePharma

As Sanofi Genzyme and Regeneron continue to add indications for their next-gen immunology treatment Dupixent, the partners have created a separateunbranded campaign to raise overall awarenessabout type 2 inflammation and its connections across multiple diseases and conditions.

The HCP-targeted Type 2 Inflammation Connection debuted at the European Respiratory Society International Congress in Octoberas the first of a planned series of events at medical congresses around the world. Its goal is to bring attention to type 2 inflammation, specifically among advocacy groups and the media, as it's a relatively new therapy area.

There is still a lot of educating to do even with who you would classify as subject matter experts in a lot of these conditions, Brian Foard, Sanofi Genzyme's global lead for dermatology and respiratory, said.

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Dupixent's on a roll in eczema and asthma, but COPD's a much tougher malady: Regeneron CEO

Marcie Ruddy, VP of clinical development respiratory and inflammation at Regeneron, said she noticed at the inaugural event that lightbulbs went off for some people when a patient spoke about his experience with multiple health conditions including atopic dermatitis, asthma and nasal polyps, which are all connectedto type 2 inflammation.

One of the reasons we launched this campaign is to help peopleunderstand that this type of inflammation can cause not just one, but often many, type 2 diseases in one patient or within one family, she said.

Sanofi and Regeneron's Dupixent is approved to treat atopic dermatitis and asthma in adolescents and adults, as well aschronic rhinosinusitis with nasal polyps in adults. The companies are also studying Dupixent in a broad range of clinical development programs in type 2 inflammation, including pediatric asthma and AD, eosinophilic esophagitis, grass allergies and peanut allergy.

RELATED: On a roll, Dupixent marches into teen eczema, nabs fast FDA review in sinusitis

The ERS congress event began with a large-scale interactive gallery, set up with photos and stories from patients and caregivers around the world. Visitors could walk through the exhibit with tablets to learn and hear more. An expert presentation from a respiratory professor at Oxford followed the walkthroughs, which then led to an open-forum discussion with a panel that included experts and researchers as well as a patient and a patient advocacy group representative.

While future events will vary based on local expert availability, the companies expect to use the same general strategy, Foard said.

See the article here:
Sanofi and Regeneron's medical congress campaign focuses on type 2 inflammation education for docs - FiercePharma